Fatty Liver Disease Clinical Trial
Official title:
Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on the Progression of Fatty Liver in Adults: a Double-blinded Randomized Placebo-controlled Clinical Trial
Verified date | September 2021 |
Source | Sun Yat-sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objectives: To examine the effects of tablets of silybum marianum, Pueraria lobate and salvia miltiorrhiza on the progression of fatty liver in patients with fatty liver. Design: a double-blinded randomized placebo-controlled clinical trial. Setting: community residents, Guangzhou city, South China. Participants: a total 118 men and women (18-65 years), with BMI range of 24-30 kg/m2, and with fatty liver screened by ultrasound or MR at baseline. Arms and Interventions: 118 participants were randomly allocated into two arms using a block randomization method. Experimental Arm: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza, 3 tablets (1g each) twice a day for 6 months; Placebo Arm: placebo tablets, 3 tablets (1g each) twice a day for 6 months. Outcome Measures: determined at baseline and at 6 months post treatment 1. Primary Outcome Measures: 1) proton density fat fraction of liver assessed by MR; 2) serum liver fibrosis biomarkers: type procollagen III N terminal peptide, hyaluronic acid, laminin, collagen type IV, and glycocholic acid; 3) NAFLD fibrosis score. 2. Secondary Outcome Measures: 1) serum liver function biomarkers: AST, ALT, GGT, ALP, total protein, and bile acids; 2) fasting blood lipids: total triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol; 3) fasting serum glucose and insulin; 4) serum inflammatory factors (hsCRP and IL-6); 5) oxidative stress: SOD and MDA; and 6) body measurements and body fat mass. Data Analyses: Mean changes in the above outcome measures from baseline to 6 months will be compared between the two arms.
Status | Active, not recruiting |
Enrollment | 118 |
Est. completion date | June 30, 2022 |
Est. primary completion date | December 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age: 18-65 years - BMI: 24-30 kg/m2 - Fatty liver, assessed by ultrasound or MR - Had normal diet and normal daily life. Exclusion Criteria: - Hospital confirmed diseases of heart, liver (viral hepatitis, drug-induced liver injury, cirrhosis), kidney, brain, hematopoietic system,diabetes, immune system, and cancer; - Taking medicine or supplements known to affect fatty liver, body fat; - Body weight had changed more than 10% within the past 3 months; - Physical or mental disabled to participate the trial; - Compliance of tablet consumption is/was less than 80% in run-in period; - Pregnant or lactating women, or intended pregnancy during the trial period; - Be allergic to the proposed supplements; - Attended or plan to attend other trial(s); - Be unwell to sign the informed consent form, or have other conditions that be not suitable to attend the trial considered by the investigators. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from baseline body weight at 6 months | Body measurement 1: Body weight (in kg) | 0 and 6 months | |
Other | Change from baseline body height at 6 months | Body measurement 2: Body height (in cm) | 0 and 6 months | |
Other | Change from baseline waist circumference at 6 months | Body measurement 3: Waist circumference (in cm) | 0 and 6 months | |
Other | Change from baseline hip circumference at 6 months | Body measurement 4: hip circumference (in cm) | 0 and 6 months | |
Other | Change from baseline anxiety score at 6 months | Anxiety Score: assessed by a Self Rating Anxiety Scale (SAS).the minimum and maximum values: 25-100 points. Higher scores mean worse outcome. | 0 and 6 months | |
Other | Number of treated events related to supplements between baseline to 6 months | Adverse/side effects: Assessed by using questionnaire of medical history, medication use, symptoms. | 0 and 6 months | |
Other | Percentage of the interventional supplements consumed between baseline to 6 months | Compliance assessment: Assessed by counting the number of remaining supplemental tablets at 6 months | at 6 months | |
Primary | Change from baseline proton density fat fraction of liver at 6 months | Proton density fat fraction of liver: measured using magnetic resonance (MR) | 0 and 6 months | |
Primary | Change from baseline liver fibrosis biomarker (Type pro-collagen III N terminal peptide) at 6 months | Liver fibrosis biomarker 1: Type pro-collagen III N terminal peptide | 0 and 6 months | |
Primary | Change from baseline liver fibrosis biomarker (hyaluronic acid) at 6 months | Liver fibrosis biomarker 2: hyaluronic acid | 0 and 6 months | |
Primary | Change from baseline liver fibrosis biomarker (laminin) at 6 months | Liver fibrosis biomarker 3: laminin | 0 and 6 months | |
Primary | Change from baseline liver fibrosis biomarker (collagen type IV) at 6 months | Liver fibrosis biomarker 4: Collagen type IV | 0 and 6 months | |
Primary | Change from baseline liver fibrosis biomarker (glycocholic acid) at 6 months | Liver fibrosis biomarker 5: Glycocholic acid | 0 and 6 months | |
Primary | Change from baseline NAFLD fibrosis score at 6 months | NAFLD fibrosis score: = -1.675 + 0.037 Age (yrs) + 0.094 BMI (kg/m2) + 1.13 impaired fasting glucose (IFG)/diabetes (yes = 1, no = 0) + 0.99 AST/ALT ratio - 0.013Platelet (*10E9/L) - 0.66 Albumin (g/dl) | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (AST) at 6 months | Liver function biomarkers 1: AST | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (ALT) at 6 months | Liver function biomarkers 2: serum ALT | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (GGT) at 6 months | Liver function biomarkers 3: serum gamma-glutamyl transpeptidase (GGT) | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (total protein) at 6 months | Liver function biomarkers 4: serum total protein | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (ALP) at 6 months | Liver function biomarkers 5: serum alkaline phosphatase (ALP) | 0 and 6 months | |
Secondary | Change from baseline liver function biomarker (bile acids) at 6 months | Liver function biomarkers 6: serum bile acids | 0 and 6 months | |
Secondary | Change from baseline fasting blood lipid (TG) at 6 months | Fasting blood lipid 1: serum triglycerides | 0 and 6 months | |
Secondary | Change from baseline fasting blood lipid (TC) at 6 months | Fasting blood lipid 2: serum total cholesterol | 0 and 6 months | |
Secondary | Change from baseline fasting blood lipid (HDL-C) at 6 months | Fasting blood lipid 3: serum high-density lipoprotein cholesterol (HDL-C) | 0 and 6 months | |
Secondary | Change from baseline fasting blood lipid (LDL-C) at 6 months | Fasting blood lipid 4: serum low-density lipoprotein cholesterol (LDL-C) | 0 and 6 months | |
Secondary | Change from baseline fasting blood glucose at 6 months | Fasting blood glucose: serum glucose | 0 and 6 months | |
Secondary | Change from baseline fasting blood insulin at 6 months | Fasting blood insulin: serum insulin | 0 and 6 months | |
Secondary | Change from baseline systolic blood pressure at 6 months | Blood pressure: systolic blood pressure | 0 and 6 months | |
Secondary | Change from baseline diastolic blood pressure at 6 months | Blood pressure: diastolic blood pressure | 0 and 6 months | |
Secondary | Change from baseline Inflammatory factor (hsCRP ) at 6 months | Inflammatory factor 1: serum high sensitivity C reactive protein (hsCRP) | 0 and 6 months | |
Secondary | Change from baseline Inflammatory factor (IL-6) at 6 months | Inflammatory factor 2: serum IL-6 | 0 and 6 months | |
Secondary | Change from baseline oxidative stress (SOD) at 6 months | Oxidative stress biomarker 1: serum SOD | 0 and 6 months | |
Secondary | Change from baseline oxidative stress (MDA) at 6 months | Oxidative stress biomarker 2: serum malondialdehyde (MDA) | 0 and 6 months | |
Secondary | Change from baseline fat mass at 6 months | Fat mass (FM): FM (kg) at total body and sub-regions determined by a dual energy x-ray absorptiometry (DXA) | 0 and 6 months | |
Secondary | Change from baseline percentage fat mass at 6 months | Percentage Fat mass (%FM): %FM (%) at total body and sub-regions determined by DXA | 0 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05881005 -
NAC- NAFLD And Cushing
|
N/A | |
Recruiting |
NCT05220956 -
Impact of Time-restricted Feeding in NAFLD
|
N/A | |
Enrolling by invitation |
NCT04066608 -
Prevalence of Advanced Fibrosis in Patients Living With HIV
|
||
Recruiting |
NCT04302051 -
Assessment of Fatty Liver With Thermo-acoustic Device
|
||
Recruiting |
NCT04496895 -
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
|
N/A | |
Recruiting |
NCT05880316 -
Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
|
N/A | |
Active, not recruiting |
NCT05898841 -
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
|
Phase 4 | |
Completed |
NCT05764811 -
SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
|
N/A | |
Recruiting |
NCT05421572 -
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
|
||
Recruiting |
NCT06302049 -
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04283942 -
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
|
N/A | |
Completed |
NCT01016418 -
Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT04175392 -
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04191044 -
Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
|
||
Not yet recruiting |
NCT06071923 -
Effect of Thyroid Disorders in Liver Diseases
|
||
Recruiting |
NCT04525833 -
Liver Disease and Other Systemic Diseases
|
||
Not yet recruiting |
NCT05966025 -
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
|
Phase 2 | |
Completed |
NCT04844450 -
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
|
Phase 1 | |
Completed |
NCT04367012 -
Fatty Liver Among Employees at Banha University
|
||
Completed |
NCT05694923 -
Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
|
N/A |